BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement

BioRestorative Therapies, Inc.

Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).
Cash & equivalents $13.1M, no debt as of Sep 30, 2024.
$230,700 product revenue from Cartessa Aesthetics supply agreement in Q3.
Blinded Phase 2 data: 70% of 10 patients at 26 wks had >30% pain reduction, >30% function increase.
No SAEs or dose-limiting toxicity at 26–52 wks; provisional NYSDOH license for allogeneic processing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.